Arm Holdings plc - American Depositary Shares (ARM)

The case for buying Boeing stock is based on its absolute and relative valuation.

One operates at the bleeding edge of AI infrastructure; the other owns the architectural blueprint powering global computing.

The Alaska Wildlife Conservation Center is a popular destination for travelers who want to experience Alaska’s wildlife and natural beauty. Located near th

The factory arm loses half as much per revenue dollar as it did a year ago -- and almost every one of those dollars is still Intel's own.

COM701 interim data expected in Q1 2027 as cash runway extends into 2029.

Bringing a newborn home for the first time is more of joy and also a quiet panic moment too. You've read the books, attended the classes, and packed the ho

The conglomerate's 16% jump looks impressive until you see which line did most of the lifting.

Arista has posted eight straight quarters of revenue gains while Arm battled volatility and federal scrutiny.

For the past decade, the global artificial intelligence boom was built on digital abundance. Massive text corpora, billions of indexed web pages, high-reso

As is so often the case, the market's come to a long-term conclusion based on short-term noise. That spells opportunity for forward-thinking investors.

Druckenmiller only owns one "Magnificent Seven" stock.

Big celebrations demand a massive upgrade in your social life. If you have a huge birthday coming up or a corporate celebration, showing up alone is a terr

A five-star hotel by itself doesn't make a trip memorable anymore, not for people who've already stayed there. What tends to stick is something smaller and

Organic sales grew 5.8% on volume gains and market share expansion across core brands.

Record financing originations and cost cuts drive adjusted EPS growth.

Record data center royalties and AI chip demand double as Arm accelerates server adoption.

Amazon's net margin expanded to 10.8% while Celsius surged 85.5% in revenue, but profitability tells a different story.

Ocugen (NASDAQ:OCGN) said its second quarter marked progress across its late-stage ophthalmology pipeline, including FDA clearance to begin a Phase III study of OCU410 in geographic atrophy and an RMAT designation for the program. Chairman, Chief Executive Officer and Co-Founder Shankar Musunuri sa

Intellia Therapeutics (NASDAQ:NTLA) said it advanced its lead gene-editing programs during the second quarter, highlighting positive Phase III results for lonvo-z in hereditary angioedema and the resumption of enrollment in Phase III studies of nex-z for transthyretin amyloidosis. Chief Executive O

Church & Dwight delivered a positive second quarter, with management highlighting broad-based organic sales growth across its divisions and strong consumer d...

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...

Today, Aug. 6, 2026, software and cloud names tumbled as investors question valuations while geopolitical tensions added fresh headwinds.

Best PRP P-Shot Clinic in Dubai | Glamorous Clinic in DubaiMen’s wellness is an important part of confidence, comfort, and overall quality of life. With ad

Generate Biomedicines focuses on AI-enabled drug discovery.

Palantir, Microsoft, and ServiceNow look like potential big AI SaaS winners.